BC Week In Review | Jul 18, 2011
Clinical News

Aviscumine: Phase II data

An open-label, German Phase II trial in 31 patients with unresectable stage IV metastatic melanoma who failed prior anti-neoplastic therapy showed that twice-weekly 350 ng subcutaneous Aviscumine led to a 3-month PFS rate of 32.3%...
BC Week In Review | Sep 21, 2009
Clinical News

CY-503: Phase II started

Cytavis began a double-blind, placebo-controlled, Austrian and German Phase II trial to compare 350 ng subcutaneous Aviscumine given twice weekly in about 250 chemotherapy-refractory patients. Cytavis BioPharma GmbH , Hamburg, Germany   Product: CY-503   Business:...
Items per page:
1 - 2 of 2